Fas expression in non-small cell lung cancerits prognostic effect in completely resected stage III patients

European Journal of Cancer

Volumn 35, Issue 10, 1999, Pages 1462-1465

  Uramoto, H ^a   Osaki, T ^a   Inoue, M ^a   Taga, S ^a   Takenoyama, M ^a   Hanagiri, T ^a   Yoshino, I ^a   Nakanishi, R ^a   Ichiyoshi, Y ^a   Yasumoto, K ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

Fas protein; Immunohistochemical analysis; Non small cell lung cancer; Prognostic factor

Indexed keywords

FAS ANTIGEN;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD95; ANTIGENS, NEOPLASM; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; FUSION PROTEINS, BCR-ABL; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032829694     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(99)00157-4     Document Type: Article

References (22)

1. Nagata S., Goldstein P. The Fas death factor. Science. 267:1995;1449-1456.
2. Trauth B.C., Klas C., Peters A.M.et al. Monoclonal antibody-mediated tumour regression by induction of apoptosis. Science. 245:1989;301-305.
3. Suda T., Takahashi T., Goldstein P., Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumour necrosis factor family. Cell. 75:1993;1169-1178.
4. Owen-schaub L.B., Yonehara S., Crump W.L., Grimm E.A. DNA fragmentation and cell death is selectively triggered in activated human lymphocytes by Fas antigen engagement. Cell Immunol. 140:1992;197-205.
5. Klas C, Debatin K-M, Jonker RR, Krammer PH. Activation interferes with the APO-1 pathway mature human T cells. Int Immunol 1993, 625-630.
6. Yonehara S., Ishii A., Yonehara M. A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. J. Exp. Med. 169:1989;1747-1756.
7. Oehm A., Behrmann I., Falk W.et al. Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily. Sequence identity with the Fas antigen. J. Biol. Chem. 267:1992;10709-10715.
8. Itoh N., Yonehara S., Ishii A.et al. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell. 66:1991;233-243.
9. Hahne M., Rimoldi D., Schroter M.et al. Melanoma cell expression of Fas (Apo-1/CD95) ligand: implications for tumor immene escape. Science. 274:1996;1363-1366.
10. O'Connell J., O'Sullivan G.C., Collins J.K., Shanahan F. The Fas counterattack. Fas mediated T cell killing by colon cancer cells expressing Fas ligand J. Exp. Med. 184:1996;1075-1082.
11. Strand S., Hofmann W.J., Hug H.et al. Lymphocytes apoptosis induced by CD95Fas (Apo-1/Fas) ligand expressing tumor cells - a mechanism of immune evasion? Nature Med. 2:1996;1361-1366.
12. Mountain C.F. Revisions in the international system for staging lung cancer. Chest. 111:1997;1710-1717.
13. Hellquist H.B., Olejnicka B., Jadner M., Andersson T., Sederholm C. Fas receptor is expressed in human lung squamous cell carcinomas, whereas bcl-2 and apoptosis are not pronounced. a preliminary report Br. J. Cancer. 76:1997;175-179.
14. Leithauser F., Dhein J., Mechtersheimer G.et al. Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor recepter superfamily, in normal and neoplastic cells. Lab Invest. 69:1993;415-429.
15. Ishida H., Irie K., Itoh T., Furukawa T., Tokunaga O. The prognostic significance of p53 and bcl-2 expression in lung adenocarcinoma and its correlation with Ki-67 growth fraction. Cancer. 15:1997;1034-1045.
16. Nishio M., Koshikawa T., Kuroishi T.et al. Prognostic significance of abnormal p53 accumulation in primary, resected non-small cell lung carcinoma. J. Clin. Oncol. 14:1996;497-502.
17. Yokota J., Sugimura T. Multiple steps in carcinogenesis involving alterations of multiple tumor suppressor genes. FASEB J. 7:1993;920-925.
18. Tsujimoto Y, Cossman J, Jaffe, Croce CM. Involvement of the bcl-2 gene in human follicular lymphoma. Science 1985, 228, 1440-1443.
19. Itoh N., Tsujimoto Y., Nagata S. Effect of bcl-2 on Fas antigen-mediated cell death. J. Immunol. 151:1993;621-627.
20. Ohsaki Y., Toyoshima E., Fujiuchi S.et al. bcl-2 and p53 protein in non-small cell lung cancers. Clin. Cancer Res. 2:1996;915-920.
21. Takahashi T., Nau M.M., Chiba I.et al. p53: a frequent target for genetic abnormalities in lung cancer. Science. 246:1989;491-494.
22. Hollstein M., Sidransky D., Vogelstein B., Harris C.C. p53 mutations in human cancers. Science. 253:1991;49-53.